corner
Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library item: 14835

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

 

Publication type: news

Hundley K.
Deaths raise questions in Indian hospital
St Petersburg Times 2008 Dec 14
http://www.tampabay.com/news/business/article934633.ece


Full text:

Rahul Verma suspected he was opening a can of worms when he filed a request under India’s new Right to Information Act.

Verma, whose critically ill son has been treated at All India Institute of Medical Sciences here, had heard parents complain that their children were not admitted because the hospital’s beds were filled with patients in clinical trials.

So last summer Verma asked the government hospital’s pediatric department these questions:

How many clinical trials have they conducted since January 2006?

How many children were involved in these trials?

How many patients died during these trials?

In the United States, a person who asked these questions of hospitals, drug companies or the FDA would get nowhere, blocked by claims of patient and corporate confidentiality. But amazingly, within a month Verma had his answers from the Delhi hospital, known as AIIMS.

Since the beginning of 2006, the pediatric department had conducted 42 trials, involving 4,142 children. Number of deaths: 49.

The news, splashed in headlines proclaiming “49 babies die,’‘ set off a firestorm. Though hospital officials documented that the deaths were due to underlying illnesses, even fellow researchers wondered why an overburdened public hospital, which handles about 500 pediatric outpatients a day, was taking on the extra work of clinical trials.

“Their primary objective should be to do patient care,’‘ said Dr. Urmila Thatte, head of clinical pharmacology at a public teaching hospital in Mumbai. “Clinical trials should not supersede that.”

Dr. Vinod K. Paul, the hospital’s head of pediatrics, dismissed claims that patient care had been slighted and was indignant at what he described as an attack on “the AIIMS’ temple of learning and innovation.” In an interview about a month after the controversy erupted, Paul itemized the causes of the 49 deaths while an assistant served tea and cookies.

A study that tried over-the-counter mouthwash to prevent sepsis in seriously ill children on ventilators accounted for 22 deaths; 21 deaths occurred in a World Health Organization-sponsored study of the potential benefit of low-cost zinc tablets for children with severe sepsis.

“Zinc tablets never kill,’‘ said Paul, pulling a bottle of the pills from a desk drawer and popping one in his mouth. “They keep me happy.”

Serious diseases, not AIIMS’ experimental therapies, killed the children, Paul said repeatedly, with the exasperation of a teacher with a slow child. Only five trials were sponsored by multinational drug companies and no one died during those trials, he said.

“I get requests from pharmaceutical companies (to do trials) every two or three weeks,’‘ said Paul, who said he usually rejects such offers. “We have no interest in being a colonial research entity. No way.”

Outside the doors of Paul’s spotless, air-conditioned office, about 4-million patients a year, among them the nation’s poorest, clamor for care from AIIMS’ doctors. They lie two per bed in the pediatric outpatient ward and pack a tiny emergency room off the hospital’s main entrance. When an ambulance from a private hospital raced up and unloaded a critically ill newborn whose parents had run out of money, Paul’s colleagues had no choice but to find space.

Verma, the father who paid 10 rupees (about 20 cents) to file his public records request, said that with space at such a premium, a government hospital shouldn’t be spending time and resources on drug studies. He also said it’s not clear how many of these studies involved poor, illiterate patients, whose parents who might not fully understand the nature of the trials.

Paul argues just the opposite, saying that the poverty of his patients only adds to the importance of AIIMS’ research work. “Twenty-two percent of the people here make less than $1 a day,” he said.

“So if I write a prescription that costs $1 a day, for that time they don’t eat. If my department cannot do research, what are we here for?”

 

  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Please
Click to Register

(read more)

then
Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts


If there is something you don't like, please tell us. If you like our work, please tell others.

Email a Friend








Far too large a section of the treatment of disease is to-day controlled by the big manufacturing pharmacists, who have enslaved us in a plausible pseudo-science...
The blind faith which some men have in medicines illustrates too often the greatest of all human capacities - the capacity for self deception...
Some one will say, Is this all your science has to tell us? Is this the outcome of decades of good clinical work, of patient study of the disease, of anxious trial in such good faith of so many drugs? Give us back the childlike trust of the fathers in antimony and in the lancet rather than this cold nihilism. Not at all! Let us accept the truth, however unpleasant it may be, and with the death rate staring us in the face, let us not be deceived with vain fancies...
we need a stern, iconoclastic spirit which leads, not to nihilism, but to an active skepticism - not the passive skepticism, born of despair, but the active skepticism born of a knowledge that recognizes its limitations and knows full well that only in this attitude of mind can true progress be made.
- William Osler 1909